Podcasts about Accreditation

“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the company's progress in its Passive Fire Protection (PFP) division, highlighting the growth opportunities ahead. Deacon explained the importance of recently receiving the BS 8670 accreditation from Construction Online, which he described as “very significant” for the business. He noted that Construction Online was originally a government department and has been supporting thousands of businesses across Europe for more than 20 years in compliance and supply chain management. According to Deacon, the new accreditation is designed to “streamline the supply pre-qualification process and will really help unblock the delays across the construction industry and supply chain.” Deacon said the accreditation will further validate Light Science Technologies' expertise across safety, leadership, risk management, and fire and life protection. He also discussed the company's pipeline, which has grown to around £28 million. Recent orders worth approximately £0.5 million have been secured across the UK, covering projects in schools, hotels, social housing, and more. Looking ahead, Deacon said both the PFP and AgTech divisions are expected to be the strongest revenue generators, with net profit anticipated for the group in 2026 as backlogs clear. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe, and enable notifications for future content. #LightScienceTechnologies #PassiveFireProtection #AgTech #ConstructionIndustry #FireSafety #UKBusiness #BuildingSafety #SupplyChain #RevenueGrowth #ProactiveInvestors

In this episode, hear from Brian Polk, Director of Accreditation at the Society for Classical Education. Learn about how SCL is doing accreditation with a view to helping classical schools flourish. Find out more about what it looks like to have a visiting team at your school and steps you can take to explore accreditation through SCL.Links from this episode:SCL Accreditation webpagePrevious episode: AccreditationThe Educational Renaissance Podcast is a production of ⁠⁠⁠⁠⁠Educational Renaissance⁠⁠⁠⁠⁠ where we promote a rebirth of ancient wisdom for the modern era. We seek to inspire educators by fusing the best of modern research with the insights of the great philosophers of education. Join us in the great conversation and share with a friend or colleague to keep the renaissance spreading.Take a deeper dive into training resources produced by Educational Renaissance such as Dr. Patrick Egan's new book entitled Training the Prophetic Voice available now through ⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠.

A simple, must-know guide to ARC-PA terms, probation vs. provisional, and how to vet programs before you hit submit. This is exactly what you need to know when it comes to PA program accreditation and applying to PA schools!CASPA SOS: Last Call Bootcamp — your step-by-step plan to submit (or strengthen) your PA school app before any more deadlines hit. Happening October 12 >> Walk in confused, walk out with a prioritized checklist, expert feedback, and a clear next step for your stage—submitted, not yet, or next cycle!Be the one who gets interviews, not rejections!→ Join now here! We can't wait to see you there! Keep up the amazing work, future PA! Beth & Katie

“I think sometimes people don't expect pediatric patients to handle radiation as well as they do. They may have a family member who also had radiation for breast cancer or for prostate cancer and they were an older adult and had really severe side effects. And then they say, ‘Oh, no, I've got to put my little baby through this. I don't really want to do this.' We say kids are very different in how they handle this. They're very resilient, so we can provide good education about that,” Elizabeth Cummings, MSN, CPNP-AC, CPHON®, radiation oncology nurse practitioner at Children's Hospital of Philadelphia in Pennsylvania, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation treatment care for pediatric patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to radiation oncology treatment care for pediatric patients. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 204: How Radiation Is Used in Palliative Care Episode 50: Difficult Decisions in Childhood Cancer ONS Voice articles: Fertility Preservation Protects Possibilities for Patients With Cancer Have Meaningful Conversations With Pediatric, Adolescent, and Young Adult Patients and Their Families Pediatric Cancer Survivors Require Additional Care and Monitoring Prepare Survivors for the Risk of Secondary Cancers Secondary Cancers in Pediatric Survivors ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS courses: Essentials in Survivorship Care for the Advanced Practice Provider ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiation Therapy Survivorship: Healthcare Providers' Perspectives on Education and Care Radiation Therapy: Understanding the Patient Experience Reducing Pediatric Patient Anxiety: Implementing a Nonpharmacologic Intervention to Aid Patients Undergoing Radiation Therapy Other ONS Resources Inclusive Care Learning Library Late Effects of Cancer Treatment Huddle Card Proton Therapy Huddle Card Radiation Huddle Card Radiation Learning Library Oncolink Jr. Pediatric Radiation Oncology Society  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “I think one of the things to think about with kids is sometimes they're not as forthcoming with what's going on, and sometimes it's a little bit harder to understand. Sometimes that's just because developmentally, they're much younger. A 1-year-old can't exactly tell you what's wrong. And so you're really trying to figure it out based on their cues versus a teenager who can tell you, but maybe they're too embarrassed about something in a way that an adult might not be.” TS 7:01 “Child life specialists are incredible. ... They provide age-appropriate education and explanations for patients, so talking to a 3-year-old about cancer is very different from an 8-year-old or even a teenager. They really are able to meet each patient exactly where they are and at the level that they are, and then provide the appropriate amount of information, which is so helpful for a patient since they learn to build trust and cope with their treatment and [they feel like they] have somebody who can relay that information in a clear and concise way.” TS 11:16 “There's certainly growing concern about the potential effects of anesthesia on brain health, especially in a vulnerable population like very young children, which are the ones who need anesthesia. We really try to mitigate this by optimizing our anesthetic agents, so we'll use propofol, which has a really quick onset and offset. And even when the radiation treatment is done, they'll stop the propofol in the radiation room—even though they are still walking back to recovery, just to minimize the amount of time that it's on—and trying to use the lowest dose possible. We also [explore] a lot of nonanesthetic strategies, [like] child life support, trying to introduce video distraction when we can, and having music and audiobooks.” TS 17:47 “[In] pediatrics, the patient, not the parent, is your patient. And that can look really different for a 3-year-old versus a 17-year-old. Somebody who can't officially sign consent, but they certainly have a lot of buy-in about the things that reach their body, versus a 3-year-old, where the parents are really taking ownership of that. I think sometimes it's tricky in the world of pediatrics as we think about the ethics of ‘Who are we training here? Is it the patients? Is it the parents?' And we continue to advocate for our patients.” TS 23:32 “I think that pediatric patients still want to be normal kids. They still want to do their normal activities. ... Our pediatric patients, a lot of times, have healthier tissues. They haven't seen as much wear and tear. They haven't developed the bad habits of some adults. They don't have the same environmental exposures, they're not smoking, they probably have fewer comorbidities. ... They're a different population. ... They're just amazing. They still want to be a kid, they still want to go to school, they still want to be with their friends. It's really encouraging to see that.” TS 36:03 

Cameron is joined by Jennifer Hartley, founder of Skin Synthesis, who shares her journey from critical care nursing to establishing her own aesthetics practice. They discuss the challenges of launching a business during the pandemic, the importance of continuous education, networking, and the philosophy behind her practice that focuses on natural results and building long-term relationships with patients. Jennifer also reflects on humbling moments in her practice and the significance of honesty and boundaries in patient care, as well as the role of technology in enhancing patient experiences.Cameron and Jennifer talk about the importance of building strong patient relationships, elevating treatment planning, and the significance of legal compliance in aesthetic practices. They emphasize the need for intentional learning at conferences and prioritizing patient care over profits,. The dialogue highlights the balance between business acumen and patient-centered care in the medical aesthetics industry.Listen In!Thank you for listening to this episode of Medical Millionaire!Takeaways:Jennifer transitioned from critical care to aesthetics to help people live well.The hustle of entrepreneurship requires grit and dedication.Investing in education is crucial for success in aesthetics.Networking is essential for support and growth in the industry.Skin Synthesis focuses on natural results and long-term patient relationships.Humbling moments in aesthetics can be profoundly impactful.Honesty and setting boundaries with patients is vital.Technology plays a significant role in enhancing patient communication.The pandemic presented unique challenges for launching a business.Confidence restoration is a key aspect of aesthetic practice. Building relationships is key to patient loyalty.Follow-up communication enhances patient retention.Elevating treatment plans can improve patient experience.Intentional learning at conferences leads to actionable insights.Legal compliance is crucial for aesthetic practices.Prioritizing patient care can lead to long-term success.Investing in team training is essential for growth.Understanding financials is important but shouldn't overshadow patient care.Accreditation can raise industry standards.Continuous passion for aesthetic medicine is vital for success.Unlock the Secrets to Success in Medical Aesthetics & Wellness with "Medical Millionaire"Welcome to "Medical Millionaire," the essential podcast for owners and entrepreneurs inMedspas, Plastic Surgery, Dermatology, Cosmetic Dental, and Elective Wellness Practices! Dive deep into marketing strategies, scaling your medical practice, attracting high-end clients, and staying ahead with the latest industry trends. Our episodes are packed with insights from industry leaders to boost revenue, enhance patient satisfaction, and master marketing techniques.Our Host, Cameron Hemphill, has been in Aesthetics for over 10 years and has supported over 1,000 Practices, including 2,300 providers. He has worked with some of the industry's most well-recognized brands, practice owners, and key opinion leaders.Tune in every week to transform your practice into a thriving, profitable venture with expert guidance on the following categories...-Marketing-CRM-Patient Bookings-Industry Trends Backed By Data-EMR's-Finance-Sales-Mindset-Workflow Automation-Technology-Tech Stack-Patient RetentionLearn how to take your Medical Aesthetics Practice from the following stages....-Startup-Growth-Optimize-Exit Inquire Here:http://get.growth99.com/mm/

Accreditation sits at the heart of higher education's promise to deliver value, quality, and opportunity. But in 2025, the landscape is shifting fast, fueled by questions of accountability, the rise of alternative accreditors, and new expectations around data and student success. In this episode of CCA on the Air, we sit down with Dr. Maria Toyoda, the new President and CEO of WSCUC. Together, we explore how WSCUC is using data to drive innovation, the role of accreditation in the evolving higher education landscape, and how accreditors can balance rigorous standards with access, student success, and innovation.

It's YOUR time to #EdUpIn this episode, part of our Academic Integrity Series, sponsored by ⁠Pangram Labs,⁠YOUR guest is ⁠Dr. Heather Perfetti, President & CEO, Middle States Commission on Higher EducationYOUR cohost is ⁠Bradley Emi , ⁠Cofounder & CTO, ⁠Pangram Labs⁠YOUR host is ⁠Elvin Freytes⁠How does Dr. Perfetti define academic integrity through the lens of accreditation standards & why does she emphasize centering students around academic rigor & holistic learning experiences? What makes Middle States Commission unique as a global institutional accreditor serving over 500 institutions worldwide & how do they work as part of the regulatory triad? How is Dr. Perfetti supporting institutions navigating AI integration while maintaining academic integrity & transparency in their accreditation processes?Listen in to #EdUpThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr. Joe Sallustio⁠⁠⁠⁠⁠● Join YOUR EdUp community at ⁠The EdUp Experience⁠We make education YOUR business!P.S. Want to get early, ad-free access & exclusive leadership content to help support the show? Then ⁠⁠​subscribe today​⁠⁠ to lock in YOUR $5.99/m lifetime supporters rate! This offer ends December 31, 2025!

This week we sit down with Lauren Bozich, MS, RD, LDN, Senior Director of Accreditation at ACEND. This episode provides an important update since our conversation with Dr. Rayane AbuSabha last year. Starting this year, all supervised practice and graduate programs accredited through ACEND must follow the new DICAS application process.Bozich walks us through the changes, explaining key dates, what they mean for students, how to prepare strong applications, and the overall benefits of this streamlined system. With her expertise, listeners will gain clarity and confidence in navigating this transition.For more details, visit ACEND's website: https://www.eatrightpro.org/acend/students-and-advancing-education/students-and-advancing-education-intro

In this episode of the Alliance Podcast, Alliance Podcast Task Force Member Andrea Zimmerman, EdD, CHCP, chats with Accreditation Council for Continuing Medical Education (ACCME) Vice President of Accreditation and Recognition Dion Richetti about accreditation myths and misconceptions that can hinder creativity and diversity in continuing education. Listen in to learn how accreditation bodies can support innovative programming while still ensuring compliance.|| LINKSAlmanac: Home | Alliance: Alliance for Continuing Education in the Health Professions | Alliance LinkedIn: Alliance For Continuing Education in the Health Professions: Posts | LinkedIn | AACME: Accreditation Council for Continuing Medical Education - ACCME | AACME LinkedIn: Accreditation Council for Continuing Medical Education (ACCME): Overview | LinkedIn | ACCME Facebook: Facebook | ACCME Instagram: https://www.instagram.com/accreditedcme | AACME Bluesky: Accreditation Council for ContinuingMedical Education (@accreditedcme.bsky.social) — Bluesky | ACCME Compliance Check Archive: News Archive - ACCME | “Coffee with Graham” Podcast: Podcast - ACCME | ACCME Compliance & Noncompliance: Compliance & Non Compliance - ACCME | ACCME Policies: Policies - ACCME | Dion Richetti LinkedIn: Dion Richetti | LinkedIn

Third week of September, what'd you miss in vet med?NY Lawmakers propose AG Oversight on AcquistionsLMU Orange Park receives COE AccreditationGallant brings education to PractionersEmbrace Pet Insurance ScholarshipTribute to my dog WalterHelpful links:The Bird Bath substackNVA: Associate Veterinarian Humber Veterinary Clinic - Job Description

This accredited CME program highlights the latest clinical research about immune thrombocytopenia (ITP), a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this program provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in ITP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with ITP and its clinical relevance.FacultyShruti Chaturvedi, MDAssistant Professor of Medicine,Johns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about iTTP, a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in iTTP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with iTTP and its clinical relevance. Shruti Chaturvedi, MDAssistant Professor of MedicineJohns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about hemophilia, a rare, genetic bleeding disorder. Led by Dr. Steven Pipe, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. This program is supported by an educational grant from Sanofi.To receive CME credit, visit https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hemophilia. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with hemophilia and its clinical relevance.Steven Pipe, MDProfessor of Medicine,University of Michigan Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Pipe discloses the following relevant financial relationships with ineligible companies:Consultant: Bayer, BioMarin, CSL Behring, Hema Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Roche/Genentech, Sanofi, Takeda, Spark TherapeuticsScientific Advisory Committee: GeneVentiv, Equilibra BioscienceGrant/Research Support: Siemens, YewSaving Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

We break down the core Circumplex orientation - Satisfaction (growth) vs Security (protection). Learn how state of mind drives behavior, why confidence is quiet, and practical ways to shift from defensiveness to growth. View the full show notes here: https://www.human-synergistics.com.au/resources/culture-insights-blog/satisfaction-vs-security-what-it-is-and-why-it-matters-culture-bites-248/ Consulting Solutions: https://www.human-synergistics.com.au/our-services/consulting/ Diagnostics: https://www.human-synergistics.com.au/our-diagnostics/ Accreditation: https://www.human-synergistics.com.au/become-accredited/

  “One powerful, overlooked aspect of colorectal cancer survivorship is the emotional and identity transformation that our survivors undergo—and really how little space is given in the clinical arena for that. No one really talks about this ‘invisible recovery.' Facing mortality can lead to prolonged changes is values, relationships, and life goals. And these experiences aren't captured in lab results or imaging scans, but they really shape how survivors live, love, and heal and continue with their lives,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 12, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase is knowledge related to colorectal cancer survivorship nursing considerations. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 374: Colorectal Cancer Treatment Considerations for Nurses Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing article: Closing the Gaps: Addressing the Unmet Needs of Cancer Survivors Oncology Nursing Forum articles: Symptom Occurrence, Frequency, and Severity During Acute Colorectal Cancer Survivorship The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS Survivorship Care Plan Huddle Card ONS Learning Libraries: Colorectal cancer Survivorship Academy of Oncology Nurse and Patient Navigators American Cancer Society National Colorectal Cancer Roundtable Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer Resource Library Livestrong at the YMCA Pan Ohio Hope Ride To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “As of the most recent data, more than 1.5 million people in the United States are living as colorectal cancer survivors. So this includes not only those who are currently undergoing active cancer treatment but also those who have completed treatment and ultimately are hopefully in remission. Just a reminder that colon cancer is the third most commonly diagnosed cancer in the United States and it's the fourth leading cause of cancer-related deaths.” TS 1:53 “Our colorectal cancer survivors may have significant barriers when receiving this comprehensive survivorship care, and these challenges can affect not only their physical recovery but their emotional well-being and, ultimately, their long-term health outcomes. We as oncology nurses do play a pivotal role in identifying and addressing these barriers. So these can include fragmented care. Who's caring for these patients? That care coordination between the oncologist and the oncology team and then the primary care providers and team. Limited access—so our patients that may have geographic limited access or also financial- or insurance-related obstacles to follow-up services.” TS 9:10 “Our nurses can also facilitate the communication between specialists and primary care providers, so making sure that we're sending records, keeping those lines of communications open. Also, nurses can provide that psychosocial support, so our screening for distress and also advocating and supporting for referral to counseling or support groups for a patient. Nurses can also act as navigators to guide these patients through complex care systems.” TS 11:21 “Some of the recommended changes—nutrition—enhancing and emphasizing fruits, vegetables, that colorful plate, with whole grains. Limit those red and processed meats, and reduce sugary drinks and alcohol. I know we will all have those patients who have read things or cancer myths about, ‘Oh, cancer feeds on sugar, so I shouldn't drink anything or eat anything with sugar,' and maybe addressing that, just really emphasizing the well-rounded meals.” TS 19:57 “When we think about [ourselves], ‘Well, I don't have an implicit bias,' but we may not think about what that is. Some common preconceived assumptions are that survivorship equals a cure. And this assumption may overlook that chronic symptoms or those late effects and emotional needs of long-term survivors. So knowing that when a patient is coming to us on surveillance, they may be cured; they may not have active cancer, but they're still dealing with some of those chronic symptoms—and acknowledging that.” TS 30:37 “There's an assumption that an ostomy equals poor quality of life, and this may stigmatize patients and discourage open conversations about adaptation and support. A couple weeks ago, I volunteered at the Pan Ohio Hope Ride, which is with the American Cancer Society, and several states have a ride that's similar. And there was a patient riding, and I could tell over his jersey that he had an ostomy bag underneath that. And I just looked at him and I thought, ‘That's amazing. You are still functioning, still living, still riding a bike throughout the entire state of Ohio with an ostomy.' So he's still having that good quality of life. That doesn't stop him from living.” TS 31:39

Host Jeremy C. Park talks with Jim Bartoo, Marketing and Public Relations Director with Nashville Zoo, who discusses the zoo's history, growth and development, and commitment to animal welfare, along with the importance of accreditation by the Association of Zoos & Aquariums. He highlights the zoo's conservation efforts, both local and global, as well as their educational programs and upcoming events. The conversation also covers the zoo's unique features, including exhibit design and animal care, and ways for the public to support and enjoy the zoo's experiences.Nashville Zoo's Philosophy and DevelopmentsDuring the interview, Jim provides an overview of Nashville Zoo's history, location, and recent developments. He explains that the zoo, which moved to its current location in 1996, has been built from the ground up, allowing for the implementation of the latest philosophies and technologies for animal care and habitat development. Jim also discusses the shift in zoo philosophy from focusing on cleanliness and sterilization to prioritizing animal welfare and creating environments that promote animal happiness and comfort.Importance of AZA Accreditation for ZoosJim discusses the importance of accreditation by the Association of Zoos & Aquariums (AZA) for zoos in the United States. He explains that while all zoos must have a USDA license for animal care, AZA accreditation goes well beyond the minimum standards, focusing on animal health, veterinary care, education, and conservation efforts. This accreditation is a gold standard for animal care and is required every five years as the standards evolve. Jim emphasizes that AZA accreditation is crucial for visitors to ensure they are supporting zoos that prioritize animal welfare.Nashville Zoo's Conservation and Education EffortsJim discusses Nashville Zoo's conservation efforts, which include local and global initiatives. The zoo works with organizations like TWRA and USDA to protect streams and environments in Tennessee, conducting head start programs and monitoring waterways. Internationally, they study animal migration patterns, such as giraffe movements in Africa, to address habitat fragmentation issues. The zoo also focuses on education, offering programs for all ages and taking ambassador animals to schools and nursing homes.Nashville Zoo Upcoming EventsJim also highlights upcoming events at Nashville Zoo, including the upcoming opening of a new exhibit, Leopard Forest, the Zzzoofari Slumber camp out on May 24, Brew at the Zoo on June 13, and Summer Splash Saturdays in July and August. Jim encourages public support through memberships, donations, and corporate sponsorships to help fund new exhibits and conservation work.Visit https://www.nashvillezoo.org to learn more.

Alzheimer's Disease Early Diagnosis and Management Evaluation and Credit:  https://www.surveymonkey.com/r/medchat82   Target Audience             This activity is targeted toward primary care physicians and advanced providers. Statement of Need A special report of Alzheimer's Disease Facts and Figures published in 2017, indicated 4 out of 5 Americans would want to know if they had Alzheimer's disease before it impacted their life. With the aging population the incidence of Alzheimer's is growing, according to the Alzheimer's Association over 7 million Americans are living with AD. This program will focus on screening and dx of AD in the early stages especially in pc offices, where patients will first present with cognitive symptoms. Additionally, this podcast will highlight the new blood biomarker test recently approved and its indications. Objectives  Differentiate between normal cognitive aging, mild cognitive impairment and early-stage Alzheimer's disease. Identify appropriate cognitive screening tools for use in primary care and their role in the early identification of Alzheimer's disease. Explain the mechanism and clinical relevance of blood-based biomarkers in the diagnosis of Alzheimer's disease, including the current guidelines and emerging practices. ModeratorRachel Hart, D.O. Geriatric Medicine Physician Memory and Cognitive Disorders Specialist Norton Neuroscience Institute Memory Center SpeakerGreg E. Cooper, M.D., Ph.D. Chief, Adult Neurology Medical Director, Memory Center Norton Neuroscience Institute   Planner Disclosure  The planners of this activity do not have any relevant financial relationships with ineligible companies to disclose. Moderator and Speaker DisclosureThe moderator, Gregory Cooper, M.D., Ph.D., discloses relevant financial relationships with Eli Lilly and Eisai (research). The speaker, Rachel Hart, D.O., discloses a relevant financial relationship with Eli Lilly (faculty).  All relevant financial relationships have been successfully mitigated. Commercial Support  There was no commercial support for this activity.  Physician CreditsAccreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Credits Norton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org.   Resources for Additional Study/ReferencesAmerican Perspectives on Early Detection of Alzheimer's Disease in the Era of Treatment https://www.alz.org/alzheimers-dementia/facts-figures   Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care https://pubmed.ncbi.nlm.nih.gov/39068545/   Date of Original Release | Sept. 2025; Information is current as of the time of recording.  Course Termination Date | Sept. 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope. Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

“

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Advancing Innovation in Manufacturing (AIM) Centre has announced the launch of its new AI Accelerator Programme for Manufacturing Companies, a ten-week hybrid initiative designed to help businesses across Ireland understand, adopt, and scale artificial intelligence effectively. For many manufacturers, the hardest part of AI adoption is knowing where to begin. AIM's new Accelerator helps turn uncertainty into action - guiding companies toward the most valuable use cases for their operations. Starting on 1st October 2025, applications are now open to manufacturing companies of all sizes and sub-sectors. The programme is delivered by the National AI Studio for Manufacturing at AIM Centre, co-funded by the Government of Ireland and the European Union through the ERDF Northern and Western Regional Programme 2021- 27. Supporting AI Adoption in Irish Manufacturing The AI Accelerator provides a structured pathway from AI strategy to deployment, enabling participating companies to build a working demonstrator tailored to their specific needs. The programme blends online delivery with in-person events, including access to Ireland's National AI Studio for Manufacturing. Over the ten weeks (one day per week) participants will gain: • A working AI demonstrator aligned with their operations, paired with a structured use case brief to support future deployment. • Guidance on integrating AI within existing ERP and data systems. • Access to industry-specific use cases, demos, and prototypes, highlighting tangible opportunities for business transformation. • Expert guidance on governance, risk, and compliance - including EU AI Act requirements. • Insights into scaling AI across operations. AIM Centre advises teams of two people attend from each company, ensuring both strategic and technical perspectives are represented. Accreditation and Funding Support The programme is CPD-accredited by Engineers Ireland, recognising its value in professional development. To support participation, SMEs can access up to 80% funding, while larger companies can also avail of significant funding support. This ensures that businesses of all sizes can take advantage of the opportunity to future-proof their operations with AI. AIM-ing for Real Results "Irish manufacturing is at a pivotal moment in its digital transformation journey. Through this programme, we aim to demystify AI and give companies the tools, confidence, and practical outcomes they need to adopt it responsibly and at scale and with measurable business impact" - David Bermingham, Director of AI, AIM Centre. How to Apply Applications are open now. To find out more or register your interest, visit: www.aimcentre.ie/ai-accelerator-programme More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

The Joint Commission's updated accreditation manual is designed to simplify requirements, enhance clarity, and better support healthcare organizations in survey preparation. In this episode of VerifiedRx, host Carolyn Liptak is joined by Dr. Robert Campbell of the Joint Commission and Diana Scott of Vizient to unpack the most significant changes. From the shift to National Performance Goals and medication safety priorities to the latest challenges in compounding, labeling, and hazardous drug handling, the conversation highlights practical insights to help pharmacy leaders stay compliant and survey-ready.   Guest speakers: Robert Campbell, PharmD, BCSCP Sr. Director, Standards Interpretation, Accreditation Decision Management,Medication Safety Division of Accreditation and Certification Operations Joint Commission   Diana Scott, MHA, RN, CPHQ Principal, Regulatory and Accreditation Services Vizient   Host:  Carolyn Liptak, , BS Pharm, MBA   Vizient   Show Notes:  [01:16-01:51] Diana and Robert Backgrounds [01:52-02:43] Changes made to the hospital and critical access hospital manuals [02:44-03:09] Changes to the chapters themselves [03:10-04:08] National Performance Goals and elaborate on those that are relevant to medication safety and pharmacy services [04:09-05:15] The top medication management challenges [05:16-06:29] Pain management not being aligned and titration orders [06:30-06:56] Insufficient communication between pharmacists, prescribers and nurses when it comes to medication orders [06:57-08:02] Themes around labeling requirements for stored medications [08:03-08:46] Anything different in removing expired meds from patient care areas and in the pharmacy this area than previous years [08:47-10:58] Issues related to storing meds specifically per the package insert [10:59-11:55] Common issues seen inside the pharmacy regarding sterile compounding, noncompliance include hand hygiene, garbing, PPE, and cleaning and disinfecting [11:56-13:12] More specifics in those area the physical environment and facility cleanliness along with cleaning and disinfection practices [13:13-14:55] Explaination of how joint Commission defines and evaluates immediate use compounding [14:56-16:09] The minimum required elements for immediate use compounding competency [16:10-17:12] Compounding competencies besides immediate use [17:13-17:54] Expectations for environmental services training [17:55- 20:14] Concerns around hazardous drugs [20:15- 21:14] Additional information   Links | Resources: Joint Commission: THE NEW STANDARD: Accreditation 360   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

“Policies help make sure that we're giving patients the right education and discharge instructions. Radiation doesn't end when the syringe is empty. Patients go home with potential radioactive exposure. They need to know how to protect their families, what precautions to take, and what healthcare providers can do if something goes wrong—like a spill, extravasation, or even a pregnant staff member who's involved in the care. This isn't just a documentation exercise. It's about making sure every part of the system speaks the same language when it comes to safety, handling, and patient care,” ONS member Ella-Mae Shupe, MSN, RN, OCN®, nursing practice and professional development specialist for radiation oncology at Johns Hopkins Health System Sydney Kimmel Cancer Center based in Baltimore, MD, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about creating and implementing radiopharmaceutical policies and procedures.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 22, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to implementing policies and procedures to support administration of radiopharmaceuticals for cancer treatment. Episode Notes   Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 104: How Radiation Affects All Areas of Oncology Nursing ONS Voice articles: New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals ONS Voice oncology drug reference sheets: Lutetium Lu 177 Dotatate Lutetium Lu 177 Vipivotide Tetraxetan Radium 223 Dichloride Sodium Iodide-131 ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS course: ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing article: Nursing Telemedicine Educational Encounters: Improved Patient Satisfaction in Radiation Therapy Clinics Other ONS resources: ONS Radiation Learning Library ONS Radiation Safety: In the Home Huddle Card ONS Radiopharmaceuticals Huddle Card Daily Med Lutathera® website for healthcare professionals Pluvicto® website for healthcare professionals Xofigo® website for healthcare professionals To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “[Lutetium lu 177 vipivotide tetraxetan] has shown so effective in clinical studies that the FDA recently approved expanded use, and it can now be given prior to chemotherapy.” TS 1:56 “There are typically three parts to a radiopharmaceutical. One is a radioisotope, which emits the radiation. The second is a targeting molecule, which directs the compound to a specific site. And the third is a linker that binds the isotope to the targeting molecules securely. The targeting molecule is usually a substance that binds specifically to receptors, antigens, or metabolic pathways that are overexpressed on cancer cells.” TS 2:08  “We have an interdisciplinary team involvement. There's a physicist, nurse, and provider that confirm lab values are within normal limits. The patient meets all the clinical and safety criteria for administration. Second is an IV placement where a nurse or clin tech starts the IV and verifies a strong blood return. This is critical to avoid extravasation, which can be harmful due to the vesicant-like nature of radiopharmaceuticals. And third, our patient voids immediately before the injection, which reduces bladder radiation dose. During the administration, our provider administers the radiopharmaceutical using a shielded syringe holder to reduce radiation exposure. The physicist remains present throughout the procedure. Lead aprons are worn by any team members close to the IV site, and then the Geiger counter is used by physics to measure ionizing radiation, which is done before, during, and after the procedure.” TS 3:28 “The policy we created doesn't just address general principles. It includes very specific guidance for both [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan]. That includes everything from determining patient eligibility to completing the treatment directive, confirming patient identity, verifying delivery parameters, documenting the treatment itself, and ensuring the treatment environment is appropriate and safe. We've also built in drug- specific practices because [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan] each come with their own considerations. This includes competencies for nursing, tailored patient education for each therapy, and an extravasation checklist that outlines what to do and who's responsible for tasks if infiltration occurs.”TS 11:24 “We created two separate versions [of an attestation model], one for clinical staff and one for non-clinical staff. Why include non-clinical staff? Because the risks extend beyond just the clinical team. What if environmental services comes in to clean and the patient has urinated on the floor? Or what if dietary delivers a tray and moves a urinal without knowing the risk? Or what if transport comes in and handles an incontinent brief without awareness? Each of these scenarios has potential for contamination and exposure. And that's exactly why education for all roles matter.” TS 15:22 “These are such an exciting treatment for our patients, that's not chemotherapy, that's not radiation, and their quality of life has been amazing. We have had patients coming in that could barely walk because of the pain from bone mets and after a few treatments, they're much better. We've had PSAs go from five, six hundreds down to 0.5, so we're seeing a lot of really good options for these patients and treatment.” TS 22:09  

In this comprehensive discussion, Bryan sits down with Brad Cooper, an experienced HVAC instructor from Arkansas, and JD Kelly, a trade school graduate, to tackle one of the most pressing questions in the HVAC industry: Is trade school worth it? Rather than offering a simple yes or no answer, the trio dives deep into the nuanced factors that determine whether trade school provides real value for aspiring HVAC technicians. The conversation begins with Brad's unique perspective as both a field technician with over 20 years of experience and a current instructor who transitioned to teaching five years ago. His father's business background and the common frustration of having to "go behind people and fix stuff" motivated Brad to enter education, believing that proper training from the start could eliminate many field problems. JD brings the student perspective, having attended trade school while working full-time, which gives him insight into both the challenges and benefits of formal HVAC education. A significant portion of the discussion focuses on what to look for when evaluating trade schools. The guests emphasize that the investment in laboratory equipment and facilities often reflects the school's commitment to the program - you can tell immediately upon walking into a lab whether the institution truly prioritizes HVAC education. They stress the importance of accreditation, particularly from organizations like HVAC Excellence, which provides regular oversight and ensures schools meet industry standards. The conversation reveals that accreditation isn't just about having a certificate on the wall; it represents a school's willingness to submit to external scrutiny and maintain educational quality. The discussion also addresses the critical balance between theoretical knowledge and practical application. All three speakers agree that the most valuable trade school experiences combine classroom learning with real-world field exposure through partnerships with local contractors, apprenticeship programs, or internship opportunities. They emphasize that instructor quality matters more than having the latest equipment - a humble, field-experienced teacher who can adapt to different student skill levels and learning styles proves far more valuable than someone with extensive theoretical knowledge but limited practical experience. Topics Covered School Evaluation Criteria Laboratory equipment quality and investment levels Accreditation importance (particularly HVAC Excellence) Modern tools vs. traditional equipment balance Manufacturer partnerships and industry connections Instructor Qualifications Field experience vs. teaching credentials Importance of humility and adaptability Managing diverse skill levels in the classroom Storytelling and practical application methods Program Length and Structure Comparison of certificate programs vs. associate degrees Benefits of two-year programs for comprehensive learning Integration of on-the-job training and apprenticeships Realistic expectations for different program lengths Hands-On Learning Importance of repetition and practical experience Managing consumable materials and budget constraints Real-world equipment exposure vs. lab simulations Peer mentoring and collaborative learning approaches Student Readiness and Expectations Managing diverse student backgrounds and skill levels Realistic employer expectations for graduates The value of combining school with field experience Personal responsibility in education and continuous learning Industry Connections Importance of school-contractor partnerships Field trip opportunities and manufacturer relationships Bridging the gap between classroom and real-world application The role of apprenticeships in comprehensive training   Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android

In this episode of What's Best For The Patient Is Best For Business, Jerry sits down with Dr. Todd Norwood, Senior Director of Clinical Services at Omada Health, a virtual care platform specializing in chronic disease management. With a background as a board-certified orthopedic and sports physical therapist, Todd shares his journey from traditional clinical practice to the forefront of digital health innovation—including his role in co-founding Physera, a telehealth startup later acquired by Omada.Jerry and Todd dive deep into the critical role of patient engagement in modern healthcare, exploring how technology can enhance outcomes while maintaining high-quality care. Todd breaks down key insights from his research, revealing how simple actions—like regular messaging between visits—can compound into significant improvements in patient adherence and clinical results. They also discuss the importance of data in proving value, the evolving landscape of telehealth, and why physical therapists must embrace digital tools to stay ahead.Key Takeaways:• Patient engagement drives outcomes: Each additional weekly message from a PT increases patient compliance with home exercises by 11%—and these effects multiply over time.• Early intervention matters: Starting care within 24 hours of sign-up boosts long-term engagement and success.• Tech is just a tool: The real skill lies in knowing when and how to use digital platforms to enhance—not replace—clinical expertise.• Data is non-negotiable: Accreditation and payer trust require proof of impact. PTs must measure outcomes rigorously to demonstrate their value.• The patient's core needs: Clear diagnosis, prognosis, and defined roles (patient + provider) are the foundation of trust and retention.Todd's research underscores a powerful truth: what's best for patients is best for business. Whether you're a clinician, practice owner, or healthcare innovator, this episode is packed with actionable insights to elevate care delivery in the digital age.

Explore the collaborative efforts at UAB Medicine that make National Accreditation Program for Rectal Cancer (NAPRC) accreditation successful. Robert Hollis, M.D., MSPH, and Ridley Brown, BSN, RN, explain how teamwork among surgeons, oncologists, and nurses streamlines patient navigation and care, ensuring that every aspect of a patient's journey is coordinated and efficient.

Crime is down 28% in Cape Coral, and in this episode of the Cape CopCast 'Chief's Chat,' we're breaking down exactly how it happened. Despite our growing population and increasing calls for service, we've achieved remarkable reductions across both violent and property crime categories while maintaining solvability rates well above national averages.What's our secret? Chief Anthony Sizemore says it's right there in our mission statement: "Partnering with the community to ensure the highest level of safety for all." This isn't just aspirational language—it's a practical approach that yields measurable results. When community members lock their doors, report suspicious activity, and maintain open lines of communication with officers, we create a foundation for success. Combine that with strategic deployment, advanced technology, and dedicated personnel who genuinely care about this city, and you've got a winning formula.We're particularly proud of our recent CALEA assessment—the gold standard in law enforcement accreditation that we've maintained since 1989. Assessors came to the department and conducted an exhaustive evaluation of our policies, procedures, and practices, from use of force guidelines to hiring practices that reflect our community's diversity. The result? The most successful evaluation in our department's history, with assessors recommending us as a national model in several areas. This recognition validates the significant innovations we've implemented over the past five years and confirms we're not just meeting standards—we're setting them.Looking ahead, we're expanding our ranks to keep pace with Cape Coral's growth, creating promotional opportunities from top to bottom within our organization. This combination of proven success, external validation, and internal development has created tremendous momentum. Have questions about our approach to community safety? Reach out—partnership is what makes this work, and we're just getting started.

Description: In this episode of Higher Ed Now, ACTA Policy Research Fellow Kyle Beltramini and Third Way Education Policy Advisor Emily Rounds discuss how accreditation became a mainstream political issue overnight. They also examine the urgent need for modernization of the current system, as well as how both Democrats and Republicans can advance reform. For more, please see their recent white paper, “Five Bipartisan Principles for Accreditation Reform.”

In this episode of the EMS One-Stop podcast, host Rob Lawrence climbs back onto his soapbox to discuss two topics that directly impact on every EMS agency in America — the CAAS Ground Vehicle Standards (GVS) 4.0 and the simple, inexpensive steps we can take to stop ambulance theft. Joining Rob is longtime EMS leader and current CAAS GVS Administrator Mark Postma, who walks us through the origins of the standards, their national adoption and what's new in the latest update. From ambulance remounting, to structural safety testing, Mark explains how GVS 4.0 has evolved to keep pace with manufacturing realities, supply chain delays and operational needs. The conversation then shifts to a shared passion for protecting fleet assets. Rob and Mark dissect the shockingly frequent problem of ambulance theft and how a $200 automatic immobilization device can prevent a $250,000 vehicle from disappearing — without relying on crews to remember to lock it. Additional resources: CAAS GVS V4.0 – Ground Vehicle Standard Commission on Accreditation of Ambulance Services (CAAS) – The New Standard in Mobile Healthcare Ambulance thefts in the U.S. surge: Over 40 stolen rigs in 18 months 6 ways to safety-proof your EMS fleet Memorable quotes "It's no good going to City Council or to your board of directors on day 365 and saying, ‘I need a new truck for New Year day one' — that's not going to happen." — Rob Lawrence "The ground vehicle standard has become the standard that most vehicles are being built to and that state EMS officials are using." — Mark Postma "We spend a lot of time thinking about where things go in the box … add one more thing to your checklist: can the vehicle indeed be immobilized?" — Rob Lawrence "There's just no reason why ambulances are being stolen with the current technology that's out there." — Mark Postma Episode timeline 00:45 – Rob introduces the topic: GVS 4.0 and ambulance theft concerns 01:34 – Mark introduction and CAAS GVS role 04:11 – How the CAAS standards were developed and adopted by 35-plus states 06:09 – Comparing CAAS GVS to NFPA ambulance standards 06:48 – The rise of remounting, especially during COVID supply shortages 10:26 – Discussion of ongoing vehicle delivery delays and need for replacement planning 15:04 – What's new in GVS 4.0 — major changes and safety structure updates 19:38 – Ambulance theft statistics and the GVS anti-theft requirement 22:28 – Automatic immobilization and why manual systems fail 23:57 – Mark shares success story: zero thefts since installing devices 26:17 – Exceptions in standards and why state inspectors must enforce anti-theft 27:42 – Final thoughts on making anti-theft part of fleet planning Enjoying the show? Email editor@ems1.com to share feedback and suggest future guests. 

Office-based anesthesia (OBA) is no longer the “wild west” of healthcare. It's a thriving, highly specialized branch of anesthesia practice that's changing the way patients experience surgery. In this episode, Lynn and Garry take you inside the rapidly growing world of OBA, where 10 million procedures a year are now performed outside hospitals and ambulatory surgery centers. They explore why patients and providers are embracing this setting, the evolving safety standards, and the anesthetic techniques that make it work. Here's some of what you'll hear in this episode:

Navigating Vaccine Hesitancy in Pediatrics Evaluation and Credit:   Navigating Vaccine Hesitancy in Pediatrics   Evaluation and Credit:  https://www.surveymonkey.com/r/medchat81 Target AudienceThis activity is targeted toward primary care physicians and advanced providers. Statement of Need Despite the availability of safe and effective vaccines, pediatricians and clinicians continue to encounter significant vaccine hesitancy among caregivers, which can lead to suboptimal immunization rates and increased risk of preventable diseases. This podcast will provide key information for providers on the causes of vaccine hesitancy and how to address with parents. In that it is a podcast, it will be a discussion with the guest and moderator. Objectives Define pediatric vaccine hesitancy and describe its impact on public health. Discuss key factors that contribute to vaccine hesitancy. Describe effective communication strategies to address parental concerns to improve vaccine confidence in pediatric care. ModeratorMark McDonald, M.D., MHA, CPE System Vice President Pediatric Medical Affairs Medical Director, Norton Children's Louisville, Kentucky SpeakerKristina Bryant, M.D. Pediatric Infectious Diseases Physician Norton Children's Infectious Diseases Chair, Norton Children's Hospital Infection Control Associate Fellowship Director Professor UofL School of Medicine Louisville, Kentucky Planner and Moderator Disclosures  The planners and moderator of this activity do not have any relevant financial relationships with ineligible companies to disclose. Speaker DisclosureThe speaker, Kristina Bryant, M.D. discloses relevant financial relationship with Sanofi as an investigator. She had relationships with Gilead, Enanta Pharmaceuticals and Pfizer as an investigator. These relationships have ended.  All relevant financial relationships have been successfully mitigated. Commercial Support  There was no commercial support for this activity.  GrantThis episode is supported by a grant from the Kentucky Medical Association's ‘Small STEPS, Big Impact' campaign, a two-year initiative that encourages patients to achieve long-term success through taking simple steps that can add up to make a big impact on their health. The campaign focuses on five key areas (screenings, tobacco use, exercise & nutrition, physician visits and stress) and offers straightforward strategies and support for patients. It is a partnership between the KMA and its charitable arm, the Kentucky Foundation for Medical, made possible by a grant from the Kentucky Department for Public Health. For more information, visit SmallSTEPSKy.org.     Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing CreditsNorton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.75 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Social Worker CreditsThe National Association of Social Workers, Kentucky Chapter (NASW-KY), is an approved provider for social work credits through the Kentucky Board of Social Work. This activity will provide 1.0 hours of required continuing education units. NASWKY # 0630/25.   Resources for Additional Study/References A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination https://pubmed.ncbi.nlm.nih.gov/38525549/ A Structural Lens Approach to Vaccine Hesitancy and Identity https://pubmed.ncbi.nlm.nih.gov/36841595/ SmallSTEPSKy.org   Date of Original Release | Aug. 2025; Information is current as of the time of recording.  Course Termination Date | Aug. 2027 Contact Information | Center for Continuing Medical EducationNavigating Vaccine Hesitancy in Pediatrics; (502) 446-5955 or cme@nortonhealthcare.org   Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope.   Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.  

Applying to PA school without checking ARC-PA status? Not a good idea. In this episode, we're making accreditation easy to understand so you can apply confidently—and avoid surprises down the road.This can change everything for you and your PA School Application: VIP Days

“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44

Downtown York is celebrating a major milestone in its journey toward revitalization — earning both state and national accreditation through the Main Street America program and the Pennsylvania Downtown Center. The recognition signals a significant accomplishment for Downtown Inc, the organization leading the charge to support small businesses, public art, economic development, and community safety in York’s core. “Accreditation is kind of the gold standard in downtown revitalization programs,” said Sarah O’Brien, Director of Downtown Inc. “York has actually been doing the work to meet those standards for many years. We just took a step back this last year and went through the process to get the recognition we’ve earned.” This is the first time in over a decade — since 2013 — that York has held the prestigious designation. Since stepping into her role in April 2024, O’Brien has worked to strengthen York’s ties to national revitalization standards and broaden the community’s participation in the process. “I worked for three different Main Street programs in Texas, and we always worked really hard to get accredited,” she said. “It was kind of a personal and team goal to get back on track with our reporting and demonstrate that we’re doing the hard work to successfully revitalize a community.” According to O’Brien, the accreditation recognizes a collaborative effort between local government, businesses, nonprofits, and private citizens. “Downtown Inc is that connector between small businesses, nonprofit organizations, government, and individuals,” she said. “Without them, we wouldn’t be where we are today.”Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

Accreditation affects everything from financial aid to institutional viability—but many board members don't realize how directly they're accountable. In this episode, AGB's Natalie Boehm talks with AGB Consultant John Cavanaugh about what every board should know: why accreditation matters, how it connects to fiduciary duties, and what questions boards should be asking. Opinions expressed in AGB podcasts are those of the speakers and not necessarily those of the organizations that employ them or of AGB.

#RonnieLo #habitcoach #drkimberleylinert #incrediblelifecreatorpodcast RonnieLo Habit Coach (Ronnie Loaiza - pronounced "Low-eye-zuh") is a Certified Habit Coach, Master Certified Professional Life Coach, and Certified Personal Trainer dedicated to helping people realize their desires and goals, one tiny step a time – that form into driving, naturally sustainable habits.Unlike quick fixes and temporary hacks that lead to burnout, Ronnie focuses on the science-backed process of creating habits- instead of forced self-discipline or constantly summing up your willpower – as that becomes exhausting.Combining her years of coaching experience with her deep understanding of behavioral science, Ronnie guides each client from identifying their true goal and the reasoning behind that goal, to taking practical action.You then convert those tiny actions into effective habits, which drive you to your goal.Her approach reprograms your 'Habitual Way of Thinking,' making positive habits a natural part of your daily routine, seamlessly aligned with your identity.Ronnie's coaching is all about support, accountability, and celebrating progress. Her pragmatic, science-based methods ensure that the habits you develop are sustainable and truly impactful.When she's not coaching, Ronnie loves dancing, watching movies, strength training, traveling, and spending time with her husband and cats.((Notes if host wants them for during or at the end of interview:))Learn more about Ronnie in 'About' at www.ronnielolifecoach.comAlso see her method of tailored coaching and how you can form habits that change your life!Master Certified Professional Life Coach (ICF Accredited)Certified Habit Coach (National Board for Health & Wellness Coaches)Certified Personal Trainer with Accreditation in Corrective Exercise, Behavior Change, Senior Fitness, Women's Fitness, Mental Toughness, and Nutrition.Contact Ronnie Loaiza:https://www.linkedin.com/in/ronnielolifecoachhttps://ronnielolifecoach.comIGRonnie Carol Loaiza (@ronnielolifecoach) • Instagram photos and videoshttps://www.instagram.com/ronnielolifecoach/Dr. Kimberley LinertSpeaker, Author, Broadcaster, Mentor, Trainer, Behavioral OptometristEvent Planners- I am available to speak at your event. Here is my media kit: https://brucemerrinscelebrityspeakers.com/portfolio/dr-kimberley-linert/To book Dr. Linert on your podcast, television show, conference, corporate training or as an expert guest please email her at incrediblelifepodcast@gmail.com or Contact Bruce Merrin at Bruce Merrin's Celebrity Speakers at merrinpr@gmail.com702.256.9199Host of the Podcast Series: Incredible Life Creator PodcastAvailable on...Apple: https://podcasts.apple.com/us/podcast/incredible-life-creator-with-dr-kimberley-linert/id1472641267Spotify: https://open.spotify.com/show/6DZE3EoHfhgcmSkxY1CvKf?si=ebe71549e7474663 and on 9 other podcast platformsAuthor of Book: "Visualizing Happiness in Every Area of Your Life"Get on Amazon:https://amzn.to/4cmTOMwWebsite: https://www.DrKimberleyLinert.comPlease subscribe, share & LISTEN! Thanks. incrediblelifepodcast@gmail.comSocial Media LinksLinkedIn: https://www.linkedin.com/in/dr-kimberley-linert-incredible-life-creator/Facebook: https://www.facebook.com/kimberley.linert/The Great Discovery eLearning Platform: https://thegreatdiscovery.com/kimberley

In this episode of The P.A.S. Report, Professor Nick Giordano is joined by Adam Kissel, author of Slacking: A Guide to Ivy League Miseducation and visiting fellow for higher education reform at The Heritage Foundation. Kissel exposes the rot inside elite institutions, from Columbia University's descent into radicalism to the broader crisis of academic decline and student activism replacing scholarship. He explains why the name on a diploma too often outweighs the quality of education received, how taxpayer dollars are fueling the problem, and what states like Florida are doing to restore civic knowledge and classical learning. This conversation is essential listening for anyone concerned about the future of American higher education. Episode Highlights: How the Ivy League became more about prestige than academic excellence Why radicalism and disruptions threaten free speech and civic discourse What states can do to bring back classical education and real accountability

求职或向他人介绍自己时，常常需要介绍自己的学习和工作经历。单词 “qualification” 和 “certification” 都可以表示 “学历，资质”，但它们之间有什么不同？为什么具有类似含义的单词 “accreditation” 则不能用于描述 “个人的学历、资格证书”？听节目，跟主持人 Beth 和步理一起辨析四个可以表示 “资格，资质” 的单词。

InTouch with Terri is brought to you by Podium: Podium is a platform providing AI-powered communication solutions for lead conversion and patient retention. In Touch with Terri listeners get their first month of Podium free CLICK HERE. Be sure to tune into the full conversation to uncover detailed insights into transforming your aesthetic practice by leveraging patient retention strategies. Subscribe for more episodes and stay informed about the latest developments and strategies in the industry  Get InTouch with Terri! Terri Ross Website: Click Here Terri Ross Patreon: Business and Sales Mentorship 4S Summit Info: For more details, look up 4S Summit to understand its role in providing strategic business consulting in the aesthetics industry https://4ssummit.com/ Terri Ross is a renowned expert in the aesthetic industry, specializing in sales training, strategic growth consulting, and business transformation. As an accomplished author and international speaker, Terri has dedicated over two decades to elevating businesses in the aesthetic field with a ground-up approach focused on sustainability, profitability, and scalability. Her experience is rooted in working with Fortune 500 companies like Medicis and Zeltique, where she developed a deep understanding of market dynamics and strategic sales methodologies. About the Guest: Thomas Terranova is the CEO of Quad A, a globally recognized accreditation body known for its dedication to surgical safety. He is an attorney by training, specializing in international mergers and acquisitions, with previous experience advising multinational corporations using data analytics. At Quad A, Thomas steers the organization's strategic direction, ensuring the adherence to quality standards across surgical and non-surgical medical aesthetic practices. Under his leadership, Quad A is pioneering a new accreditation initiative for non-surgical medical aesthetics to enhance patient safety and facility standards worldwide. Quad A Website: quada.org Episode Summary: Welcome to this engaging episode of "In Touch with Terri," where we explore the dynamic world of accreditation in the booming aesthetics industry. Host Terri Ross converses with Thomas Terranova, CEO of Quad A, about an exciting and crucial initiative to introduce a global accreditation framework for non-surgical medical aesthetic practices, such as med spas. As the industry surges ahead with rapid growth, this initiative aims to bridge the current regulatory gap, providing a structured and formal oversight mechanism that has long been absent in non-surgical environments. In this revealing discussion, Terri and Thomas delve into the pressing safety gaps in the medical aesthetics sector. With an understanding that current growth has outpaced both regulations and common best practices, Thomas outlines the steps Quad A is taking to standardize safety, excellence, and consistency. The pair highlight the potential impacts of this initiative on both practitioners—ensuring legitimate, safe operations—and patients who will gain increased confidence in the services they receive. Attentive listeners will learn about the core pillars of this new accreditation framework, the challenges faced during its development, and its anticipated positive repercussions on the global stage. Key Takeaways: The medical aesthetics industry is experiencing rapid growth but lacks adequate regulation, particularly in non-surgical environments such as med spas. Quad A, under the leadership of Thomas Terranova, is leading a global initiative to develop an accreditation framework for non-surgical medical aesthetic practices. The accreditation aims to ensure patient safety, enhance facility standards, and instill greater confidence in aesthetic treatments. The initiative includes comprehensive documentation, rigorous staff training, and the adoption of standard operating procedures to minimize risks. Educating patients and making safety considerations front-and-center are key strategies for improving consumer trust and industry standards. Notable Quotes: "If you're a well-intentioned practitioner, whatever we're talking about are nothing to be afraid of. The only people that should be afraid are the people who don't want to do things right." "Product is a big one. And again, with supply chain, the way it is... that's a huge concern." "It's a choice to do things the right way. It's a choice to do it in a way that's safe." "We're bringing this back to medicine. We're talking about making sure the products are valid, properly maintained, and that the staff is well-trained."

Episode 252: Most CX maturity assessments ask how you think you're doing. This one demands proof. Erin Wallace, director of client engagement at MyCX from Bain & Company, is helping to lead a fundamental shift in how companies measure CX maturity. Most tools rely on perception-based self-assessments that reward self-promotion over progress. The Customer Experience Roadmap and Accreditation (CXRA) demands verifiable proof—evidence against 55 global, industry-backed standards. It's not always comfortable, but it's often the turning point. Bain's CXRA challenges the internal echo chamber. Erin explains how most assessments rely on surveys sent to a handful of CX insiders, producing a distorted view of reality. The CXRA demands documentation of policies, processes, behaviors, and measurable outcomes such as customer experience metrics, operational KPIs, or business results. It uses outside-in validation to confront that distortion. This isn't academic. It's where things get real. Leaders often push back. Some insist, “We're better than this.” Others admit, “We're not as good as we might think.” That tension is the point. Because CXRA doesn't just assess quality—it measures how consistently CX practices are applied across the business. That's how it exposes the “pockets of brilliance” that never scale, leaving most customers with a fragmented, uneven experience and leadership teams with a false sense of progress. For many leaders, conducting the CXRA offers clarity they've never achieved: a shared fact base, benchmarks of world-class practice, and a clear path forward. It doesn't just reveal what's missing, it builds the conviction to fix it. Guest: Erin Wallace, Director of Client Engagement, Bain & Company Host: Rob Markey, Partner, Bain & Company Give Us Feedback: Help us improve the podcast (feedback link) Key Topics Covered 01:00 – Why perception-based CX tools fall short 02:20 – What defines a successful evidence-based assessment 03:10 – The challenge with identifying “pockets of brilliance” 04:15 – How companies respond to uncomfortable truths 05:40 – Aligning leaders around what “good” really looks like 06:55 – Using 55 global standards to benchmark performance 08:10 – What Bain's CX Roadmap and Accreditation assesses 09:30 – What Erin learned at the X4 2025 Conference in Salt Lake City Time-Stamped Notable Quotes [5:00] “MyCX℠ is  a tool anyone in the industry can use, whether you're a strategic advisor, a technology implementer, or a CX practitioner. These should be things we agree on in terms of the standard of excellence for culture, capabilities, and execution.” [6:00]  “Most maturity assessments—tools to understand where you are and how you're doing with CX—are survey-based. They're perception-based. We send [them] out to a couple hundred people in the company, see what they think, and how they think they're doing with CX. You usually get back a pretty inactionable result. What's different about MyCX Roadmap and Accreditation, which is based on these global standards, is that it's an evidence-based, outside-in assessment.” [7:00] “It's an opportunity to dig in and have a conversation. And to evaluate the perception with the policy against results.” [8:00] “We look at quality, coverage, and consistency of application across the business. There could very well be a spotlight—like pockets of excellence—that are not applied across the organization in a meaningful way.” “[9:00] “What does good look like, and is that really what we aspire to accomplish? And then what will it take to get there? Because oftentimes, everyone has a different opinion of what is ‘good.' And do we really want to get there? This helps [organizations] break through and get that bigger investment unlock that's required to lead.” Learn more about Bain & Company's CX Roadmap and Accreditation process: https://www.bain.com/consulting-services/customer-strategy-and-marketing/customer-experience-transformation/mycx/ Learn more about the Global CX Standards: https://www.netpromotersystem.com/resources/cx-standards/

The news of Texas covered today includes:Our Lone Star story of the day: The first called session of the 89th Legislature is underway in Austin as of Noon today. Congressional redistricting takes the national spotlight but there is a long list of highly important items on the Governor's call – it is probably too much for one 30-day session.Speaker of the House Burrows, founder of the Bureaucrat Coalition, named a special committee for redistricting. On the surface it looks heavily tilted to Republicans until one realizes that the 3-vote GOP majority on the committee is offset by Burrows appointment of three of the most liberal RINOs to the committee: Geren, Hunter, and Guillen.Our Lone Star story of the day is sponsored by Allied Compliance Services providing the best service in DOT, business and personal drug and alcohol testing since 1995.Busting two common myths about Property Taxes perpetuated by politicians and  local media.Records show DEI standards used to pressure law schools to adopt racist practices. Texas law school deans (including at Texas Tech) want to deep DEI-infused ABA accreditation!Republican launches TX34 House bid in key Rio Grande Valley swing district GOP aims to flip in 2026 midterms – Eric Flores.Listen on the radio, or station stream, at 5pm Central. Click for our radio and streaming affiliates.www.PrattonTexas.com

Too often, distance learning gets dismissed as fragmented or disjointed, seen as a patchwork of tech tools rather than a cohesive educational system. Teachers feel pulled in too many directions, and programs struggle to sustain impact beyond the novelty of going virtual.In this episode, Dr. Chris Harrington - leader of the EmpowerEd Research Institute, AccredVEd, and Digital Learning Works - shares how real transformation happens when virtual education is approached as a system. From curriculum to leadership to parent engagement, Chris lays out what it means to create a student-centered, coherent virtual learning ecosystem. He introduces specialized accreditation processes, discusses how to build systems around people - not tech - and shares inspiring stories from the field, including how one virtual program helped a struggling student graduate against the odds.If you're building - or rebuilding - a distance learning program, listen in for insights on:Why cohesion is the key to long-term success in virtual education.How to lead systems change with clarity, equity, and community buy-in.The power of specialized accreditation to elevate—not just evaluate—program quality.What it really means to put relationships at the center of digital learning.Episode Links:Digital Learning WORKSEmpowerEd Research InstituteAccredVEdHost Links:Discover more virtual learning opportunities and resources at CILC.org with Tami Moehring and Allyson Mitchell.Seth Fleischauer's Banyan Global Learning provides meaningful global learning experiences that prepare students across the globe for success in an interconnected world.

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35

Episode 251: In 2018, Dell set out to do something big: turn customer feedback into a system that could not only provide insights, but help set priorities and run the business. They had the data. They had the intent. But they made a compromise that many organizations settle on: Rather than enforce one unified approach to customer feedback, they allowed each team to build its own. While this helped with initial adoption and change management, it also led to fragmentation—multiple tools, different methods, no shared truth. And it got worse over time. Real progress ultimately would require centralizing what had become scattered. When Dell's Marc Stein appeared on this podcast in 2018 (episode 129), the company had just completed its EMC merger and launched a chief customer office. The ambition: one integrated Net Promoter System to tie sentiment to economics and put the customer at the center of every decision. But good intentions ran into a harsh reality: Every function was listening to customers, but no one was hearing the same thing.  In this episode, Mike Valanzola, Dell's Senior Director of Voice of Customer and NPS Operations, picks up the story. He explains how misaligned tools, siloed ownership, and governance gaps made customer feedback hard to act on. His team didn't want to tear down what existed. Instead, they brought it together. Through consolidation, centralization, shared standards, and stronger governance, they transformed scattered signals into an enterprise-wide system of action. The turning point came with the Customer Experience Roadmap and Accreditation. The CXRA gave Dell a framework to drive internal accountability and rebuild trust in the system. As Mike describes, cross-functional teams now meet weekly to act on shared signals. Tomorrow's goal? Make every employee a promoter and make every signal actionable. Guest: Mike Valanzola, Senior Director, Voice of Customer and NPS Operations, Dell Technologies Host: Rob Markey, Partner, Bain & Company Give us feedback: Customer Confidential Podcast Feedback Send us a note: Contact Rob Time-Stamped Topics 00:01 - Marc Stein's 2018 ambition: a unified CX system 03:50 - Why integration faltered: fragmentation, politics, data overload 06:20 - Mike's mission: centralize tools, enforce governance 10:00 - Transforming custom systems to create shared accountability 13:30 - Early delivery surprises and sentiment gaps 17:10 - Predictive models and operational fixes 21:00 - How Dell built trust in the new NPS engine 27:45 - Weekly action meetings: turning listening into doing 35:30 - Why CXRA certification mattered, internally and externally 40:00 - Reflections on past company decisions Notable Quotes “ We have a robust  partner community that allows us to  expand our scale in terms of the customers that we can  touch. Each and every one of those folks has some things that are important for us to hear.” [8:00]  ”We do—and did—as a company, listen regularly, but we didn't always hear. The reason for that came down to every function across the company, ultimately doing their own listening programs, using their own application, governing how they listened, controlling what they got back, and not sharing it.” [18:00]  ”We had been really in a run-the-business function, really focused on  NPS management, really focused on owning  that measurement for the company. And now, I was proposing a large-scale, end-to-end corporate transformation that was going to require my own team  to think about how we operate, and effectively operate differently.” [28:00] Additional Resources Hear our 2018 podcast with Marc Stein on Dell's original CX ambition, Bringing Net Promoter to Scale Learn more about Bain's MyCX Roadmap & Accreditation

Republican-led states, spearheaded by Florida Governor Ron DeSantis, are launching a new accreditation body for higher education, aiming to dismantle existing standards deemed 'ideologically biased.' This move seeks to strip colleges of diversity, equity, and inclusion initiatives, replacing robust academic curricula with 'anti-woke' content focused solely on workforce metrics and conservative dogma. It's a transparent ploy to cultivate a less critically thinking populace, benefit dubious institutions like 'Trump University,' and funnel taxpayer money to politically aligned ventures. This attack on comprehensive education prioritizes control and revenue over intellectual development, turning higher learning into an echo chamber for a narrow ideology, ultimately undermining the very fabric of an informed citizenry.News Source:Universities Creating New Accreditation Agency In Some Republican StatesBy Dan Levin and Karah Rucker for Straight Arrow NewsJune 27, 2025

In this episode, Dr. Nathaniel Wilson provides some brief updates and then shares news regarding the recent accreditation of Wilson Academy Online.

Plus, Linda Yaccarino steps down as CEO of X after two years on the job. And U.S. measles cases hit a 33-year high. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: AI-Assisted Colonoscopy Can Detect Small Colon Polyps As Colorectal Cancer Incidence Increases in Younger Patients, USPSTF Issues New Screening Guidelines. Here's How Nurses Can Encourage Uptake Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Text Messaging Reduces Disparities in Colorectal Cancer Screening USPSTF Recommends Colorectal Cancer Screening Should Begin at 45 Clinical Journal of Oncology Nursing articles: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Colorectal Cancer Screening: A Quality Improvement Initiative Using a Bilingual Patient Navigator, Mobile Technology, and Fecal Immunochemical Testing to Engage Hispanic Adults Oncology Nursing Forum article: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data ONS Course: Prevention, Detection, and the Science of Cancer—Oncology RN ONS Biomarker Database ONS Colorectal Cancer Learning Library American Cancer Society colorectal cancer resources Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42 “[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there's a huge impact on early detection.” TS 4:07 “Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25 “Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29 “Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53 “Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you're like, ‘There's no way they're going to agree to that, so I'm just not going to offer it.' Where we don't offer it, they don't have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18

Ever wonder what happens when you invest in a syndication? In this episode, hosts Tait Duryea and Ryan Gibson break down how real estate syndications work, from deal sourcing and underwriting to legal docs, fees, and investor returns. Learn how passive investors get access to large-scale deals, what to look for in a sponsor, and what happens after you wire the funds. If you're considering a syndication, this is your essential primer.Show notes:(0:00) Intro(03:11) Why syndications open new doors(05:02) What is a real estate syndication?(07:20) Inside a $102M portfolio deal(09:50) How deals are sourced and vetted(11:38) Fee structures: who gets what(17:13) Key documents: PPM, OA, subscription(23:28) How to title your investment(29:20) Accreditation: requirements and process(37:58) What happens after you invest(42:00) Outro